General Information

Targeting Microbiota 2023 Replay & Abstracts Book are Available

CoverA4 TargetingMicrobiota 2023

Targeting Microbiota 2023 - Replay Access

Targeting Microbiota 2023 Recordings are now available for replay. You can get access to all recorded presentations for 3 weeks. On-demand content make it easier for you to access the presentations at your convenience. 
 
22 hours of presentations on Microbiota
62+ presentations (major talks and short orals)
 

Targeting Microbiota 2023 Abstracts Book

The 10th edition of Targeting Microbiota digital abstracts book compiles 62+ abstracts: from major talks to Short Oral and Poster Presentations. It also includes speaker details and emails for direct connections. 

Order Abstracts Book.


Targeting Microbiota 2023 Congress - Replay + Abstracts Book

You can benefit from Targeting Microbiota 2023 Recording access + Abstract Book together for a clearer vision and a better Targeting Microbiota Conference experience.

Order both abstracts book and the replay. 

 

Phage-Microbiome Consortium: Interplay and Modulation in Human Health and Disease

The ISM is pleased to announce the launch of The Phage-Microbiome Consortium.

Aim of the Consortium

The aim of this project is to set up a consortium of experts in the field of bacteriophages and the human microbiome, to collectively explore the potential of phages in shaping and modulating the microbiome in the context of human health and disease. The consortium will work in teams to push the boundaries of current knowledge, through collaborative research and knowledge exchange.


Objectives

1. Understand the Phage-Microbiota Interaction:
The consortium will carry out integrated studies to enhance the understanding of phage-bacteria dynamics and the role of phages in maintaining microbial diversity and stability.

2. Explore the Potential of Phage Therapy:
Teams will investigate the potential of phages as alternative therapeutic agents for various diseases, focusing particularly on conditions associated with microbiome dysbiosis and antibiotic resistance.

3. Identify Phage Biomarkers:
The consortium will work to identify specific changes in phage populations associated with different health conditions, thus facilitating disease prediction, diagnosis, and treatment.

4. Promote Phage Engineering:
With advancements in genetic engineering, the consortium will explore possibilities to create engineered phages with enhanced efficiency, broader spectrums, and other desirable properties.

5. Establish Regulatory and Safety Guidelines:
Recognizing the lack of robust regulatory guidelines for phage therapy, the consortium will also work towards proposing safe and effective guidelines.


What is expected?

The expected outcome of this project is to offer new insights into the complex interplay between phages and the human microbiome and to pave the way for innovative, effective, and personalized phage therapies. By bridging the expertise gap, we aim to leverage the immense potential of phages in treating diseases and promoting human health.


Project Modalities and Application Procedure

To contribute to this Consortium, the ISM requests interested researchers and teams to submit a proposal. Below are the guidelines to respect:

1. Team Formation:
Interested teams should consist of a diverse range of experts with substantial knowledge and experience in bacteriophages, microbiota, or related fields. Each team should ideally have at least one expert in bacteriophages and one in microbiota.

2. Proposal Submission:
Teams should submit a detailed project proposal that outlines their planned research, including objectives, methodologies, expected outcomes, and the timeline for the project. Proposals should demonstrate a clear understanding of the interplay between phages and the microbiome and should propose innovative approaches to explore and modulate this relationship in the context of human health and disease. They should also clearly state how the work contributes to the broader objectives of the consortium.

3. Review Process:
Proposals will be reviewed by a panel of experts in the field. Successful proposals will be selected based on their scientific merit, feasibility, and potential impact on our understanding of the phage-microbiome interplay.


Funding

The consortium will actively seek funding from both private and public institutions to support the selected projects. The collected funding will be distributed to all teams involved in the Consortium.


How to Submit?

Please submit your projects and details above:

- At the following email address: microbiota(at)microbiota-site.com. 

- Deadline for the submission: October 1, 2024.  

Applications will be reviewed by the Consortium Selection Committee, and successful applicants will be contacted to proceed to the next stage of the process. Please note that acceptance into the consortium is competitive, and only a select number of applicants will be chosen to join.


Role of the International Society of Microbiota

The International Society of Microbiota will act as the principal coordinator and manager of this consortium. The Society will facilitate the integration of teams and will foster the exchange of knowledge and expertise amongst the participants.

In its role as coordinator, the Society will ensure that all projects align with the consortium's overarching goals. It will provide guidance and direction to ensure that research efforts are complementary and additive. The Society will also help in harmonizing data collection and sharing across teams to promote a more comprehensive understanding of the phage-microbiome relationship.

The ISM, will supervise the allocation and utilization of consortium-provided funds, ensuring they are used effectively and efficiently. It will liaise with private and public funding institutions, advocating for the consortium's work and securing additional resources.

Through this central role, the International Society of Microbiota aims to unite global expertise and drive forward the understanding of the pivotal role of phages in modulating the microbiome and influencing human health and disease.


Logo ISM2022International Society of Microbiota
Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice

 

Abstract & Project Submissions

The International Society of Microbiota (ISM) invites researchers, healthcare professionals, industry experts, and startups to submit abstracts and project proposals that align with the conference’s themes and objectives. This is an excellent opportunity to share  your cutting-edge research, innovative projects, and impactful ideas with a global audience.

Targeting Microbiota 2023 is excited to host an Innovation Showcase, providing a dedicated platform for startups, industry leaders, and innovators to demonstrate their groundbreaking technologies, products, and services in the field of microbiota research.

2 submission types are available:

1. Regular Abstract Submission

Researchers and professionals are encouraged to submit abstracts highlighting their work in the field of microbiota. Abstracts should provide a concise summary of the research objectives, methods, key findings, and their implications in future research. Accepted abstracts will be presented as posters or oral presentations during the conference sessions, allowing participants to showcase their work and engage in fruitful discussions.

Targeting Microbiota 2023 is also excited to host an Innovation Showcase, providing a dedicated platform for startups, industry leaders, and innovators to demonstrate their groundbreaking technologies, products, and services in the field of microbiota research. Participants in the Innovation Showcase will have the chance to showcase their products through interactive displays, demonstrations, and presentations. 

Deadline for Oral Presentations Submission: September 30, 2023.

Deadline for Innovation Submission: September 30, 2023.

Deadline for Posters Presentations Submission: October 7, 2023.

Submission Guidelines & Modalities.


2. Project Proposals

In addition to abstract submissions, the conference welcomes project proposals that offer new insights into the complex interplay between phages and the human microbiome and to pave the way for innovative, effective, and personalized phage therapies. Proposals should outline the project’s objectives, methodologies, expected outcomes, and potential impact in the field. Accepted project proposals may have the opportunity to be featured in dedicated sessions or workshops during the conference, providing a platform to discuss and collaborate with other participants.

Learn more about the Phage-Microbiome Consortium.

Deadline for Project Proposal Submission: September 1, 2023.

About the ISM Phage-Microbiome Consortium

Logo ISM2022 2

The newly launched Phage-Microbiome Consortium of the ISM aims to offer new insights into the complex interplay between phages and the human microbiome and to pave the way for innovative, effective, and personalized phage therapies. The ISM invites all interested parties to submit proposals & join the consortium.

Phage microbiome consortium

Who Attended Targeting Microbiota 2023?

Industries
BellaVie
BIOCODEX
Bioscientifica
Copan Italia SpA
Dr. Schär
Gnosis by LeSaffre
ImmunoBiome
L'Oréal R&I
MedibiotiX GmbH
SYNLAB MVZ Leinfelden-Echterdingen
Unifarco Spa
Uwe Zeeb Gebäudedienste & Umwelttechnik
Vet-Med-Labor Zrt. 
Percheron Bioceutical
 
Academies
Academy of Silesia, Gyncentrum sp. z o.o.
Acibadem Maslak Hospital, Dept Obstetrics & Gynecology
Aristotle University of Thessaloniki
Baylor College of Medicine
BiomedicalCenter Speyer
BMR GENOMICS SRL
Clinical Microbiomics
Department of Experimental Biology, Faculty of Science, Masaryk University
DPC Hospital
East Lancashire Hospitals NHS Trust
Evomed Luxembourg
FISABIO
Florida International University
Furtwangen University of Applied Sciences
Herbalife Nutrition
INIBIC
INRAe
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
Instituto Nacional de Saúde Dr Ricardo Jorge
Institutul Clinic Fundeni
Kaiserlautern University of Applied Sciences
Karolinska Institutet
Korea Food Research Institute
Korea Research Institute of Bioscience & Biotechnology
KU Leuven
LAMPOVET SRL
LUHS Hospital Kaunas Clinics
Masaryk University, Faculty of Science
Masarykova univerzita
Massachusetts General Hospital
Mayo Clinic
Medical Treatment Center of Microbial Medicine
Medical University of Warsaw
MHB
Microbiology Laboratory, Medical School of A.U.Th.
National University of Singapore
Nofima
PI "National Laboratory Astana"
Practice for Internal Medicine
Queen's University Belfast - SBS
Samsung Advanced Institute for Health Sciences and Technology
sc centrul medical unirea srl
Scuola Normale Superiore
SEMMELWEIS UNIVERSITY
Shree Ramkrishna Intitute of computer education and Applied Science
St. Anne's University Hospital in Brno
Sungkyunkwan University
TargEDys
Teaching Hospital of the University of Jena
The Chinese University of Hong Kong
The Institute of Microbiome and Applied Science
The Seventh Affiliated Hospital of Southern Medical University
The University of Chicago
UGent
United Arab Emirates University
Universidade de Santiago de Compostela
Università Ca' Foscari Venezia
Universitat Rovira i Virgili
University College London
University of Arkansas
University of Bologna
University of Copenhagen
University of Florida
University of Genoa
University of Gothenburg
University of Lausanne
University of Leipzig
University of Medicine and Pharmacy "Grigore T. Popa" 
University of Padova
University of Pennsylvania
University of Texas Southwestern Medical Center
University of Zagreb School of Medicine, Center for Translational and Clinical Research
USDA-ARS Poultry Production and Product Safety Research Unit
Weill Cornell Medicine in Qatar

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next